Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study
Sorfequiline (TBAJ-876) is a novel diarylquinoline under development for tuberculosis. In a first-in-human, multiple-ascending-dose study, electrocardiogram and pharmacokinetic data were analyzed to assess cardiac repolarization. Placebo-corrected change-from-baseline in QTcF (ΔΔQTcF) ranged from -11.4 to +2.4 ms without dose dependency. Concentration-QTc modeling showed a shallow, non-significant slope. The predicted mean effect on ΔΔQTcF at the maximum geometric mean C<sub>max</sub> of sorfequiline's M3 metabolite was -1.1 ms (90% CI -9.5 to 7.4).CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT06058299.
Authors
- Rebecca S. Bruning-Barry
- Börje Darpö
- Jerry Nedelman (ORCID: https://orcid.org/0000-0002-0205-522X)
- Robert Kleiman (ORCID: https://orcid.org/0000-0003-0333-9045)
- H. Xue
- Antonio Lombardi
- Dean Hickman
Institutions
- Clarion University (US)
- RTI International (US)
- TB Alliance (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1128/aac.01273-25
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00